EULAR 2024 Preview: What’s Not to Miss?

The European Alliance of Associations for Rheumatology (EULAR) 2024 European Congress of Rheumatology Annual Meeting is able to contrivance shut space in Vienna, Austria. From June 12-15, some of the arena’s main researchers and clinicians will convene to point to and rep out about files on some of the unusual and progressive remedies for of us with rheumatic and musculoskeletal ailments (RMDs) as well to to chat in regards to the vogue to make exhaust of and optimize present approaches. 

Ahead of the Congress, Medscape Scientific News asked the Congress Committee’s Scientific Programme Chair Caroline Ospelt, MD, PhD, and Summary Chair Christian Dejaco, MD, PhD, MBA, to chat about a few of their highlights of this three hundred and sixty five days’s meeting. 

From Bench to Bedside

“For me, the beauty at EULAR is truly that you just have got got the most contemporary on classic analysis, how this will likely be translated in scientific trials, after which the closing step will likely be how EULAR recommends it to be archaic in scientific practice,” Ospelt mentioned in an interview. She is a professor of experimental rheumatology at College Health center Zurich in Switzerland. 

“So, when you happen to head to EULAR constantly, it is possible you’ll presumably presumably presumably truly practice the total story of how novelty comes into scientific practice,” she added. 

In a separate interview, Dejaco, a e-book rheumatologist and accomplice professor on the Scientific College of Graz in Austria, mentioned: “There are a total lot of unusual drug trials which are going to be offered.” 

One of his highlights on the exhaust of present medication for the medication of big cell arteritis stands out as the portion 3 SELECT-GCA trial of the Janus kinase (JAK) inhibitor upadacitinib (LBA0001). 

“It is a ways a trial that with any luck will lead to the approval of this drug on this indication,” Dejaco mentioned. 

Gradual-Breaking Abstracts

Ospelt eminent: “We had a total lot of staunch unhurried-breaking abstracts this three hundred and sixty five days.” 

A range of these contain: 

• Right-world files on the comparative effectiveness of five varied lessons of gear archaic to treat psoriatic arthritis (PsA; LBA0002) 
• The 16-week results of a portion 2b/3 look with the radical interleukin (IL)–17A inhibitor izokibep in of us with PsA (LBA0005)
• Recordsdata from the COSPIRIT-JIA trial on the efficacy and safety of ixekizumab (Taltz) in juvenile idiopathic arthritis (LBA0009)
• Portion 2 files on the protection and efficacy of the CD38-concentrating on monoclonal antibody daratumumab in systemic lupus erythematosus (LBA0007)
• Results of the portion 2 DAHLIAS look of the anti–neonatal Fc receptor monoclonal antibody nipocalimab in of us with well-known Sjögren disease (LBA0010) 
• Safety and immunogenicity files from a portion 1 look of an brisk anti–IL-6 immunotherapy in of us with knee osteoarthritis (LBA0011)

The latter is “truly attention-grabbing,” Ospelt mentioned. As of now, there is now not a licensed medicine for osteoarthritis, and there is now not a immunotherapy, “so that is also the well-known.” 

However or now not it is now not upright the unhurried-breaker abstracts to acknowledge out for. Dejaco highlighted two abstracts that will likely be offered right by the Summary Plenary: 

• A portion 3 look of a unusual selective JAK1 inhibitor, SHR0302, in rheumatoid arthritis (OP0037)
• A multi-omics analysis and focused gene-editing look in of us with VEXAS syndrome, which causes inflammatory and hematologic modifications (OP0073)

Of the latter he mentioned, “this disease is composed incompletely understood, and this abstract truly helps to better ticket the mechanisms underlying this disease.” 

One to Detect: CAR T-Cell Therapy 

Ospelt mentioned that the scientific program is ready 80% scientific and 20% classic science total. On the replacement hand, more sessions are being held collectively because files are initiating to switch from the bench to bedside. 

One of many most well-known science areas that has had “a trusty buzz” round it and is now producing results within the sanatorium is the exhaust of chimeric antigen receptor (CAR) T cells. In one of the well-known, and probably aptly titled What Is Novel, or WIN, sessions of the congress, Georg Schett, MD, vice chairman of analysis at Friedrich-Alexander-Universität Erlangen-Nüremberg in Germany, will talk about the exhaust of CAR T-cell treatment for inflammatory RMDs. There are additionally more than one abstract shows on this matter. 

In-depth tissue analysis and prediction of medication response is one other attention-grabbing approach, Ospelt mentioned. “I discover that’s the capability to head, that we come from the blood, we race into the tissue.” A “very good” instance of this approach will likely be offered right by the Summary Plenary session on Wednesday, June 12, taking a recognize at how synovial tissue macrophages would possibly presumably also presumably give files on likely medicine response in medicine-naive rheumatoid arthritis (OP0062). There are additionally some extra findings connected to the tissue biopsy–pushed medicine trial R4RA which are being offered on the meeting (OP0218, OP0242, and POS0351). 

EULAR Highlighted Classes

Amongst the highlighted sessions on the EULAR 2024 web space is a session on axial involvement in PsA and spondyloarthritis (SpA). 

“Axial involvement in psoriatic arthritis and peripheral involvement in axial spondyloarthritis is extremely a sizzling matter within the meanwhile,” Ospelt mentioned. There are a entire bunch questions: “How linked are they? How varied are they? Assemble we need varied medicine for axial involvement in contrast to peripheral involvement?” 

One other EULAR highlighted session is the 75th anniversary of glucocorticoid medicine, right by which Past President of EULAR and Emeritus Professor of Rheumatology Josef S. Smolen, MD, will overview the “past, point to, and future” of glucocorticoids in RMDs. Manual rheumatologist Frank Buttgereit, MD, from the German Rheumatism Be taught Center in Berlin, will talk about the practicalities of the exhaust of these medication in scientific practice.

Dejaco eminent: “Glucocorticoids have been one of the greatest remedies for a truly long time, and they also’re composed the greatest medicine for the acute medicine of systemic inflammatory ailments.” 

For a in point of fact long time, there become no replacement to the exhaust of steroids, he added, however steroid-sparing alternate options now exist, and there’ll likely be files offered on unusual sort of drug that will presumably also doubtlessly be archaic to govern cortisol ranges within the body (OP0335). 

Suggestions and More

Ospelt and Dejaco both pointed out other sessions which are inclined to be very in vogue, such because the well-known and second EULAR Suggestions sessions, a session on rheumatoid arthritis prevention, as well to the varied shows and sessions on digital health and nonpharmacologic interventions similar to exercise. 

With over 5242 submitted abstracts, there goes to be no shortage of files being offered at EULAR 2024. Alongside the archaic abstract submission categories, this three hundred and sixty five days there is a unusual scientific case experiences class. 

“We had about 578 submissions for that class,” Dejaco mentioned. There have been 3315 abstracts submitted for the scientific analysis class, 812 for the most well-known and translational analysis class, 283 from health consultants in rheumatology, 152 from affected person teams, and 102 within the field of pediatric rheumatology. 

Join in On-Advise, Detect on Question 

EULAR 2024 reverts to an on-space–handiest meeting this three hundred and sixty five days. One of the well-known well-known more mild-hearted but tutorial ingredients of this technique for these attending contain the second model of the EMEUNET Rheumatology Quiz and, unusual for this three hundred and sixty five days, two rep away rooms. These rooms will present an interactive abilities the build exiguous teams will must resolve rheumatologic conundrums in uncover to flee the room throughout the hour, Dejaco defined. There will additionally be a morning budge on Friday, June 14. “It is now not a travel, or now not it is merely to fulfill and budge collectively,” Dejaco mentioned. 

However when you happen to can’t invent the Congress in person, the EULAR 2024 Livestream will likely be broadcasting throughout the congress. Anybody registered by June 30 will have on-ask access to the recorded relate from June 17 till December 31, 2024. 

Abstracts for the meeting will likely be printed as a supplement to Annals of the Rheumatic Diseases, the genuine journal of EULAR. 

Ospelt experiences no connected financial relationships. Dejaco has received consulting/speaker’s charges from AbbVie, Eli Lilly, Janssen, Sparrow, Novartis, Pfizer, Roche, Galapagos, and Sanofi.

Sara Freeman is a scientific journalist and writer based in London, UK. She is a ordinary contributor to Medscape Scientific News, Medscape News UK, and other specialist healthcare media shops.